These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 27564469

  • 1. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
    Cervera C, Cofan F, Hernandez C, Soy D, Marcos MA, Sanclemente G, Bodro M, Moreno A, Diekmann F, Campistol JM, Oppenheimer F.
    Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
    [Abstract] [Full Text] [Related]

  • 2. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
    Radtke J, Dietze N, Spetzler VN, Fischer L, Achilles EG, Li J, Scheidat S, Thaiss F, Nashan B, Koch M.
    Transpl Infect Dis; 2016 Feb; 18(1):79-88. PubMed ID: 26707694
    [Abstract] [Full Text] [Related]

  • 3. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
    Fernández-Ruiz M, Arias M, Campistol JM, Navarro D, Gómez-Huertas E, Gómez-Márquez G, Díaz JM, Hernández D, Bernal-Blanco G, Cofan F, Jimeno L, Franco-Esteve A, González E, Moreso FJ, Gómez-Alamillo C, Mendiluce A, Luna-Huerta E, Aguado JM, OPERA Study Group.
    Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
    [Abstract] [Full Text] [Related]

  • 4. Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients.
    Ozaki KS, Câmara NO, Galante NZ, Camargo LF, Pacheco-Silva A.
    Int Immunopharmacol; 2005 Jan; 5(1):103-6. PubMed ID: 15589467
    [Abstract] [Full Text] [Related]

  • 5. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
    Montero N, Quero M, Melilli E, Pérez-Sáez MJ, Redondo-Pachón D, Bestard O, Crespo M, Cruzado JM, Pascual J.
    Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
    [Abstract] [Full Text] [Related]

  • 6. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T, Borges K, Williams A, Banh T, Vasilevska-Ristovska J, Allen U, Parekh RS, Hébert D.
    Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
    [Abstract] [Full Text] [Related]

  • 7. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction.
    Luan FL.
    Transplant Proc; 2013 Aug; 45(1):175-7. PubMed ID: 23267799
    [Abstract] [Full Text] [Related]

  • 8. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.
    Lim WH, Eris J, Kanellis J, Pussell B, Wiid Z, Witcombe D, Russ GR.
    Am J Transplant; 2014 Sep; 14(9):2106-19. PubMed ID: 25088685
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
    Hoerning A, Wilde B, Wang J, Tebbe B, Jing L, Wang X, Jian F, Zhu J, Dolff S, Kribben A, Hoyer PF, Witzke O.
    Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
    [Abstract] [Full Text] [Related]

  • 10. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
    Basso G, Felipe CR, Cristelli MP, Mansur Siliano J, Viana L, Ferreira Brigido AN, Stopa Martins SB, de Castro Lima Santos DW, Aguiar WF, Tedesco-Silva Junior H, Medina-Pestana JO.
    Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
    [Abstract] [Full Text] [Related]

  • 11. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.
    Transplant Proc; 2004 Aug; 36(6):1847-9. PubMed ID: 15350495
    [Abstract] [Full Text] [Related]

  • 12. Experience with belatacept rescue therapy in kidney transplant recipients.
    Brakemeier S, Kannenkeril D, Dürr M, Braun T, Bachmann F, Schmidt D, Wiesener M, Budde K.
    Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
    [Abstract] [Full Text] [Related]

  • 13. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP, Esmeraldo RM, Pinto CM, Sandes-Freitas TV, Felipe C, Lobo CF, Viana L, Mansur J, Stopa S, Santos DWC, Grenzi PC, Aguiar WF, Tedesco-Silva H, Pestana JOM.
    Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
    [Abstract] [Full Text] [Related]

  • 14. Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.
    Cristelli MP, Felipe CR, Prizmic PSS, de Azevedo VFD, Viana LA, Tavares MG, Wagner de Castro Lima Santos D, de Paula MI, Medina-Pestana JO, Tedesco-Silva Junior H.
    Clin Transplant; 2019 Oct; 33(10):e13689. PubMed ID: 31400155
    [Abstract] [Full Text] [Related]

  • 15. Impact of ganciclovir prophylaxis on cytomegalovirus infection in recipients of cadaveric renal allografts.
    Ram Peddi V, Hariharan S, Schroeder TJ, First MR.
    Nephron; 1997 Oct; 76(1):49-55. PubMed ID: 9171300
    [Abstract] [Full Text] [Related]

  • 16. Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zeng J, Zhong Q, Feng X, Li L, Feng S, Fan Y, Song T, Huang Z, Wang X, Lin T.
    Front Immunol; 2021 Oct; 12():663602. PubMed ID: 34539621
    [Abstract] [Full Text] [Related]

  • 17. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Glover TE, Watson CJ, Gibbs P, Bradley JA, Ntzani EE, Kosmoliaptsis V.
    Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
    [Abstract] [Full Text] [Related]

  • 18. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
    Tanrısev M, Ayna Kılıçaslan T, Çolak H, Ersan S, Yılmaz B, Alp A, Tuğmen C, Sevgili BE.
    Ann Transplant; 2021 Sep 17; 26():e932434. PubMed ID: 34531361
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, Rohrer R.
    Clin Transplant; 1997 Oct 17; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [Abstract] [Full Text] [Related]

  • 20. Real life experience with mTOR-inhibitors after lung transplantation.
    Bos S, De Sadeleer LJ, Yserbyt J, Dupont LJ, Godinas L, Verleden GM, Ceulemans LJ, Vanaudenaerde BM, Vos R.
    Int Immunopharmacol; 2021 May 17; 94():107501. PubMed ID: 33647822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.